Literature DB >> 15105586

Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.

Lia Pulsatelli1, Paolo Dolzani, Tania Silvestri, Paolo Caraceni, Andrea Facchini, Giovanni Ravaglia, Carlo Salvarani, Riccardo Melicòni, Erminia Mariani.   

Abstract

Recently, novel members of the TNF/TNF receptor superfamily, receptor activator of nuclear factor- kappa B ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediators of both the immune system and bone functions. The balance of RANK/RANK-L and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. In order to evaluate whether RANKL/OPG balance is modified by ageing, we analyzed, by imunoassay, systemic levels of OPG and sRANKL in healthy elderly subjects (age range from 70 to over 90 years) and in patients affected by two age-related diseases, osteoarthritis (OA) and polymyalgia rheumatica (PMR), characterized by bone metabolism alteration and involvement of the immune system. We demonstrated that (a) plasma concentrations of OPG increased significantly with age; (b) conversely, sRANKL significantly declined in the group of subjects aged between 81 and 90 years, being similar to the young controls in the other age groups; (c) in OA and PMR, circulating OPG did not differ from plasma levels found in age-matched control groups, while sRANKL concentration was significantly increased compared to controls. Hence, in ageing, the sRANKL/OPG system appears to be modified, with prominent changes in circulating OPG levels; in OA and PMR, the sRANKL/OPG balance alteration was shown to be mainly due to the increase of plasma sRANKL concentration. Copyright 2004 Kluwer Academic Publishers

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105586     DOI: 10.1023/B:BGEN.0000025075.04136.ec

Source DB:  PubMed          Journal:  Biogerontology        ISSN: 1389-5729            Impact factor:   4.277


  9 in total

Review 1.  Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders.

Authors:  Natalia Carrillo-López; Laura Martínez-Arias; Jorge B Cannata-Andía; Manuel Naves-Díaz; Sara Panizo; Sara Fernández-Villabrille; María Piedad Ruiz-Torres; Adriana Dusso
Journal:  Calcif Tissue Int       Date:  2021-02-13       Impact factor: 4.333

2.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis.

Authors:  Daniela Stupphann; Martina Rauner; Dagmar Krenbek; Janina Patsch; Thomas Pirker; Christian Muschitz; Heinrich Resch; Peter Pietschmann
Journal:  Rheumatol Int       Date:  2008-03-28       Impact factor: 2.631

4.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.

Authors:  H Uemura; T Yasui; Y Miyatani; M Yamada; M Hiyoshi; K Arisawa; M Irahara
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 5.  Calcium metabolism and vitamin D in the extreme longevity.

Authors:  Giovanni Passeri; Rosanna Vescovini; Paolo Sansoni; Carlo Galli; Claudio Franceschi; Mario Passeri
Journal:  Exp Gerontol       Date:  2007-07-04       Impact factor: 4.032

Review 6.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

7.  The impact of nonosteogenic factors on the expression of osteoprotegerin and RANKL during human fracture healing.

Authors:  Julia Starlinger; Georg Kaiser; Anita Thomas; Kambiz Sarahrudi
Journal:  Bone Joint Res       Date:  2019-08-02       Impact factor: 5.853

8.  Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.

Authors:  C E Evans; S Mylchreest; J G Andrew
Journal:  BMC Musculoskelet Disord       Date:  2006-03-06       Impact factor: 2.362

9.  Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data.

Authors:  Hui Heng Chua; Sharifah Emilia Tuan Sharif; Wan Faisham Nu'man Wan Ismail; Muhamad Syahrul Fitri Zawawi; Sarimah Abdullah
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.